{
    "clinical_study": {
        "@rank": "33427", 
        "arm_group": [
            {
                "arm_group_label": "Day 1", 
                "arm_group_type": "Experimental", 
                "description": "Cangrelor IV (2h) + oral prasugrel (60mg) administered within 5 minutes after cangrelor IV discontinuation (n=6)\nor\nCangrelor IV (2h) + oral prasugrel (60mg) administered at infusion time 1.5h (n=6)"
            }, 
            {
                "arm_group_label": "Day 8", 
                "arm_group_type": "Experimental", 
                "description": "Prasugrel discontinued 24h (n=6) or 48h (n=6) prior to initiation of cangrelor infusion (2h)"
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate that patients treated with cangrelor can be directly switched to oral\n      prasugrel and that patients treated with prasugrel can be switched to cangrelor without a\n      significant decrease in the extent of  inhibition of platelet aggregation."
        }, 
        "brief_title": "Cangrelor Prasugrel Transition Study", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. greater than / equal to 18 and less than 75 years of age\n\n          2. stable coronary artery disease defined by the following criteria\n\n               1. Previous myocardial infarction defined by admission to the hospital with\n                  elevation of markers of injury or the presence of pathologic Q waves on at least\n                  2 contiguous electrocardiogram (ECG) leads.\n\n                  OR\n\n               2. Previous revascularization by PCI or CABG. AND\n\n               3. Treatment with ASA 81 mg daily."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852019", 
            "org_study_id": "MDCO-CAN-13-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Day 1", 
                    "Day 8"
                ], 
                "description": "Cangrelor IV is administered as a 30 \u00b5g/kg bolus, followed by 4 \u00b5g/kg/min infusion for two hours on study Days 1 and 8", 
                "intervention_name": "cangrelor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Day 1", 
                    "Day 8"
                ], 
                "description": "Subjects will receive prasugrel (60 mg) either during the initial cangrelor infusion (at 1.5 hours \u00b15 minutes, n=6) or within 5  minutes of discontinuing the cangrelor infusion (n=6).  Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours.", 
                "intervention_name": "Prasugrel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cangrelor", 
                "Prasugrel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "CAD", 
        "lastchanged_date": "August 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Burlington", 
                    "country": "United States", 
                    "state": "Vermont", 
                    "zip": "05401"
                }, 
                "name": "Fletcher Allen Health Care"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study of the Transition From IV Cangrelor to Oral Prasugrel, and Prasugrel to Cangrelor, in Patients With Coronary Artery Disease.", 
        "overall_official": {
            "affiliation": "Fletcher Allen Health Care", 
            "last_name": "David J. Schneider", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Assessment of effect is with terminal/final light transmission aggregation (LTA) in response to 20 \u00b5M ADP.\nCangrelor alone = (at Timepoint 1, either at 1.5 hours or 2 hours)\nPrasugrel alone = (measured 3 hours after prasugrel dosing on Day 1)", 
            "measure": "Extent to which inhibitory effect is preserved during the transition period (change over time) compared with the effect observed with cangrelor alone or prasugrel alone.", 
            "safety_issue": "No", 
            "time_frame": "Day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852019"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Day 8, change in inhibition from prasugrel alone (first timepoint on Day 1) to  cangrelor plus prasugrel (next point.) assessed with final LTA, 20 \u00b5M ADP.", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 8"
            }, 
            {
                "measure": "Day 8, change in inhibition from prasugrel alone (first timepoint on Day 1) to  cangrelor plus prasugrel (next point.) assessed with VerifyNow PRU.", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 8"
            }, 
            {
                "measure": "Bleeding events in accordance with the GUSTO scale", 
                "safety_issue": "Yes", 
                "time_frame": "Day 8"
            }, 
            {
                "measure": "Day 8, change in inhibition from prasugrel alone (first timepoint on Day 1) to  cangrelor plus prasugrel (next point.) assessed with by flow cytometry.", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 8"
            }
        ], 
        "source": "The Medicines Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Medicines Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}